Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
100% agree- Adding to this, there is the "private reply" option as well, hello! Don't whine about responses if you choose the "public reply" option.
i agree - this seems to be a very good board, even with WIC / Researcher duking it out on the playground. all points of view are appreciated bull or bear as long as they are rooted in facts or at least some well thought out speculation (investing is, after all, nothing more than educated speculating)
as a comparative, on the TRXC board here we have a bearish moderator that regularly posts untrue information and deletes legitimate bullish posts. quite bad if you ask me...
yeh thanks for the laugh and I could not resist hamming it up. we all have our strategies. as long as it's working, that's what matters :D
"The reasoning being if it is meant to be, it will execute. " ROFL!! Sorry that is one of the funniest things I have ever heard- Shall we call it Karmatic Investing? Hey can I copyright that term? I'm buying the domain name right now... lol
Sefu sez: "Grasshopper...you must be one with the bid".
Jedi master sez: "This is not the ask you are looking for"
Yoda sez: "Slap that ask you will"
not bad, however, i would look at the top CBD-related companies, either in online sales and distribution of their own finished CBD product or are engaged in large scale production of CBD.
these companies have not really run yet on their stock prices whereas a lot of the plant growers have.
POTN is a #1 pick. MJNA, FRLF, VDRM, GRNH potential strong plays.
JMHO
I agree- that is why i wanted to see if it is possibly on the company radar. for example POTN is earning well, in process of getting uplisted, and retired half of the common shares. excellent value going forward- i'm thinking MJNA is as well, but they do need to reduce the # of shares at some point. still a good buy though - making money and executing on plans.
question- how do we gain long term share price appreciation with 2.8b outstanding shares? market cap is a significant multiple of the very good revenue and growth. i'm bullish on the company and outlook but a bit unsure of the potential for share price appreciation based on the current structure. anyone hear info on a possible up-listing or share reduction?
i'm a regular retail investor. tried calling the investor contact of record and its just a voice mailbox. no callback.
Wow- very good news piece! https://www.prnewswire.com/news-releases/pot-stocks-gearing-up-for-strong-2018-as-cannabis-cbd-frenzy-intensifies-663633773.html
POTN is first mention. I also like MJNA
500k dump = Sign lender converting note shares to revenue (more then likely). it only feels like a big deal when there are a low number of buyers. IMO most of the eyeballs and new money traders are glued to bitcoin / crypto currency / blockchain related. that can only last for so long and MJ-related is the current untapped overlooked sector.
good morning - nice news. I suppose this reminds all longs the company is executing and moving forward as planned. I still think we should be at or near .10 right now. jmo.
sounds about right to me based on the FDA test report data! thanks for quoting.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm580452.htm
I would suggest reading the actual FDA comments, which I included a link to in my post. regardless of what Sport or i have to say on it, or interpret it, that is the correct info from the FDA on results and it says nothing about test results of "similar". end of story.
That is why i like to post the actual data with my comments when i can, if someone does not like how i'm stating it then you can read the actual truth for yourself.
where is the foundation for clearance results based on "similar" and showing that Senhance results were not substantially equivalent to Davinci? ?
if Senhance were not equally as effective as Davinci during the FDA test track, it would not have been determined 'substantially equivalent'. it would have been determined 'non equivalent' or 'less than equivalent'. or one could even say 'similar'. Similar and equivalent are two vastly different determinations.
Some of these FDA reports use big words and complex, overly specific phrasing, but it is still English.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm580452.htm
Yep that's pretty much it- I don't mind the contrary point of view as long as it is rooted in complete fact and not partial (or complete) fiction.
These robots are big ticket items. right now hospitals have been doing budgeting for FY2018. they won't be submitting any POs for robots until at least Q1.
in the meantime, TRXC needs to stay afloat until the POs come rolling in and sometimes that means raising cash. they can sell equity in company to VC, or offer up a chunk of common shares from the authorized pool (that is why an authorized pool exists!). It's all just business 101.
Early investors with eye on the prize just sit tight, hold long, and believe in your homework. ...Or not.. Sell your shares, move on to a better opportunity for you.
it does crack me up though when I read "opinions" about things like share offerings (e.g. so called dilution) from folks who have obviously never started, run a company, or held a C-level position. Would be nice if we all had Jeff Bezos there to write us a big check when needed but that is not reality.
Point is - as long as the company is executing, moving forward, meeting obligations and milestones, and the story is still good- let them raise some cash when needed. while you may call it "dilution", that cash raise is helping to build long term value and eventually a higher share price.
jmho
substantially equivalent is syn with equally effective in this case. You do realize "equivalent" means "equal". right?
You said "similar". FDA does not test for "similarity". if Senhance testing was not equally as effective as DaVinci it would not have been cleared. There is no other truth except that one, no matter how much you wish it to be so.
Since you admit no wrong, you are claiming that the FDA cleared Senhance for "similarity".
I'm open to new info, just back it up with facts. Tell us then how the FDA testing and clearance process works for granting 501(k) clearance based on 'similarity'. You do know enough about it based on your claims, to speak on it intelligently correct?
You also are claiming i suggest a BO or partnership from ISRG. 100% false fact / I never said that. I've posted more than once that I do not think it is a good idea and is unlikely a this time.
Hmm- I never said ISRG was going to buy TRXC, nor have I ever suggested it as a good idea. where you get that from?
when you are a publicly traded company your responsibility is to the shareholders and major changes are voted on by the board. company purchase decisions are run by bean counters looking to increase bottom line profit and ER numbers. no one on the board would approve spending even 10m on updating their robotic tech because of the monopoly. its not like a hospital is going to buy anyone else's lapro bot, newer or not.
Your view of the FDA clearance info is completely wrong.
FDA reports as follows: "FDA concluded that these study data, supported by real-world evidence, along with performance testing under simulated use and worst-case scenario conditions, demonstrated the substantial equivalence of the Senhance System to the da Vinci Si IS3000 device for gynecological and colorectal procedures."
Laymen terms "equally effective" = "substantial equivalence", syn.
e.g. : "substantial" and "equivalent" - google definition of those words. are you sure you know what "equivalent" means?
FDA demonstrated that the Senhance device is substantially equivalent to a legally marketed predicate device (DaVinci).
FDA granted clearance of the Senhance System to TransEnterix Surgical Inc.
If FDA test had only shown Senhance to be "similar" as you claim, it would have failed.
JMO, it's not cool to offer false facts in a stock message forum.
here is the FDA report: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm580452.htm
I agree with that- its going to be all about the order pipeline and booked sales. i did not expect the stock price to be above $6 until then. certainly didn't expect it to be undervalued at present levels but that did happen to ISRG as well. If an investor believes the long term gold then this is simply an extended buying opportunity.
its outright silly! FDA track is a long (years!), arduous and very expensive process (10's of millions to 100's of millions!). it's the holy grail and validation of a company's hard work / dedication to excellence. TRXC getting this FDA clearance in such a lucrative area of med is huge!
this long time and huge expense is why ISRG never added any real features or updates to davinci, it would have cost millions each time.
Not only that but if they resubmitted their bot to FDA for approval of features the FDA may have made then update a bunch of stuff relating to core design of the robot or fail it altogether.
Essentially, no need with the stronghold monopoly- "buy our old bot, keep buying the overpriced replacement tools, and shut up". basically no one had a choice until now
that's one question that easily answers itself. ISRG had a monopoly. no need to spend big money on new tech when you can keep selling your captive market the same old robot and same old overpriced consumables, rinse / repeat, and milk it for everything possible. that $100m went into the exec pockets instead. to date ISRG has ignored urgent customer requests for things like haptic feedback, reusable tools, comfort for surgeon, and instead did some weak offering of a watered down old bot with a lower price point. that is hilarious. talk about giving your customers the big finger.
since Senhance was proven by FDA to be at least as effective as Davinci, eventually hospitals are going to go with the robot that has these requested features, lower TCI and AFAIK better purchase pricing / lease options.
combine that with all of the lawsuits building against ISRG and it is crazy to think that Senhance will not sell units.
unfortunately no one expected the WACKO suicide vest bomber this morning on NYC. that put the markets on alert but were still green.
my heart goes out to families of the 4 killed. during the holiday season no less.
bull market today should be wild with BTC trading futures.
its an interesting thought but i disagree- whatever does or does not happen this week is inconsequential to LT gains. IMO we will not see a lot of upside momentum until after 01/2018. right now is time to pick the potential winners and get in cheap.
Nkerimi- well put together.
Keep in mind Russell 2k is down 1.30% instead of being up 3% in December, as is historically common. All of my plays right now are small cap focused. Also I'm looking at call options on the IWM for Jan, that should be up easily.
basically we're on hold this end of year with getting new investor money. guaranteed anything small cap and promising will run in early 2018. Especially when fools stop bidding up BTC- that is going to pull back after the futures start trading next week and it can be properly shorted. parabolic always comes back down! Brokerages like coinbase are going to literally cr@p when they are left holding the bag on BTC currency that is declining in value, with no buyers (they have to buy it then sell it as the middleman). once the BTC area feels shaky, traders / investors will start looking at stocks again, and pot related are untapped!
Pot related stocks are all going to kill it this year, as long as they are not scam companies running on false promises and no track record of execution or even knowledge of this area. this is a highly undervalued area and investors are going to come in droves once it catches eyeballs again with the double and triple digit quarterly sales increases posted by many of these companies. e.g "follow the money" and "get in early"
IMO - online sales focused companies will make the most money along with growers and cbd producers.
7 good plays for 2018: https://finance.yahoo.com/news/7-strong-buy-disruptive-stocks-182106997.html#
I'm long TRXC as I feel that has 100x upside and the greatest potential
quite a few stocks went nowhere this week. its an odd time right now with tax law changes, end of year tax related selling, a missile happy dictator in N Korea, and bitcoin building a crazy bubble.
have a good weekend
i hold a lot of shares around 2.65 average bought all the way up to 3.30 but imo anything you buy now under $10 is a winning ticket.
lets put it this way, it is like buying ISRG all over again. either TRXC is bought out for $20+ per share or takes 30%-50% of the market away from ISRG, becomes the new dominant leader. either way it is ridiculously undervalued and not on main investment radar yet. its free money waiting to be printed for early investors.
the CEO used to work at JnJ, sales exec and staff stolen from ISRG, they all have the knowledge and contacts to succeed. company has plenty of funding, will not be diluting, no warrants to be exercised, etc etc.
the downside is it is not an immediate satisfaction scenario it is a buy hold and get rich in 3-5 years. ISRG was $6 / share post FDA approval, dropped to $2 / share after that, and is now at over $1000/share split adjusted with a 146x multiple
The sales ramp up time for TRXC should be 10x quicker since ISRG had the tough task of convincing hospitals to even look at a robot (they were like- "..a robot for WHAT?.." back in those days). now robotic assisted surgery is the growing standard.
Researcher- Whomever that is, it is for a different area of surgery- spinal I believe, or for setting surgical screws, brain tissue, or something like that.
as far as ISRG they were the only approved robot for soft tissue abdominal, gyno, recto etc. now we have TRXC as the only other approved robot. this is a 60+ billion market worldwide for soft tissue surgical related procedures. it is the largest market worldwide for robotic procedures
no one else will be able to enter this robotic area for at least 5 years, even if they started the FDA approval process today. Medtronic is closest but still 3-5 years out. JnJ blew it.
hey aren't you the "researcher"? (LOL kidding with you).
you've just described 90% of all publicly traded companies. lol.
My all time fav story is ISRG - split adjusted it ran from pennies to over $1000/share. they had a monopoly on FDA approved soft tissue surgical robot until this year. they had been literally raping hospitals forever with an old outdated robot, and selling extremely expensive replaceable surgical instruments for it. The hospitals all had to pay because there was no other FDA approved laparoscopic / soft tissue robot.
now that there is a new competitor this year with a newer robot, monopoly is over- just about all of the execs started cashing out blocks of shares right after the last ER. Quite hilarious. the party is ending. but hey i give them respect for creating the monopoly and racket. the sad part is if they were not so greedy they could have remained on top forever by updating their robot and making it more cost effective. they refused to meet any customer requests for things like haptic feedback and reusable instruments, head tracking, which the new competitor robot has (TRXC). obviously, the ISRG CEO should be fired for incompetency but he'll have a big golden parachute.
the Forbes info is one of the reasons I bought POTN over PURA. Dispensaries are the smaller beneficiary of CBD profits. Yet PURA with zero sales, no real experience in the CBD/MJ space, no current pipeline, the share price doubles. while POTN with great YoY earnings, product, pipeline and greater CBD profit potential, heads lower?
Sometimes stocks make zero sense and defy the solid fundamentals. that is where investor patience comes into play.
I think you may be overthinking it. this is simply "business 101" - Sign takes a big risk on speculative company, Sign expects a decent repayment term. and the upside is POTN has access to plenty of capital to grow and execute.
There is nothing bad going on here, it is normal fare for a small public startup seeking large funding.
I'm saying this as a CEO and going through my own rounds of capital raises. My company is not public, however either way (public or private) there are very little avenues to obtain reasonable capital terms.
1. VC firm- give up large % of ownership equity
2. Bank - pay outrageous interest rates and have a pathetic funds limit
3. Toxic debt- Obtain a very high funds limit and offer repayment as converting note to shares
Most all pub companies on the OTC markets will opt for toxic debt / converting notes as it makes the most sense - If the company is legit and successful, the end goal will be to get out from under it and obtain better sources of funding, and that is what it looks like POTN is on track to do
That said, Sign does need to sell shares to make back their money + profit, they area business with employees etc. they won;t do anything to purposefully harm the company as that is their money. it only seems bad when they sell a chunk of shares due to lack of new buyers / bidders.
JMO
yes that is generally correct. however that by itself is not a bad thing. it is how the lender gets paid back for lending money, and they do have interest in seeing share price increase. although at the present share price level it represents a significant gain on their as-issued price.
if we have a lot of buyers and investor interest coming in, then this small amount of regular Sign dumping is insignificant.
PR is very important. for example, PURA has doubled in the past couple of days based on nothing more than "LOI" announcement, and no possible earnings for quite some time. Good PR gets new money attention.
Meanwhile this company has real earnings and growth, but remains quiet. I'd agree the 'Sign' block share selling is wrecking price movement. but if there are more buyers than sellers it won't matter. but we won't get new buyers without visibility, e.g. PR.
yes Bull- i agree on ACBFF for long term as long as they keep increasing revenue and earnings potential. Whats even funnier is I almost bought PURA instead of POTN the other day but decided not to since they are not as stable and not actually earning anything yet. but today it ran up over 20% on a general report with est. higher price target. I guess we just need to wait our turn here. heh. hey don't we have one of those "higher price target" reports out too?
I looked into AGTK, not making any money yet / too speculative. Will wait to see rev first. Look at FRLF and GRNH instead, both making money and showing good YoY growth. APHQF and TWMJF are good solid plays too but I'd wait for a bit more pullback on each.
very well put together. other items in our favor will be investor money rotating back into the pot related stocks, and POTN is one of the more solid, favorable prospects for LTH.
As for today's trading I'm not sure why the sudden price weakness unless it is end of year tax-related selling. i don't think any retail investors holding long are going to sell shares this soon for peanuts. I do see some big bids lined up hoping to get in or add to positions cheap today.
i think the market needs to catch up - this is one of the only MJ-related penny stocks that actually has earnings, product pipeline, has track record of executing on plans successfully, and is not an absolute mess financially.
IMO we should be closer to 0.10 at this point.
Q3 2017 earnings report: http://www.otcmarkets.com/financialReportViewer?symbol=POTN&id=183954
supplemental to the report - page 5 has current legal, accounting and IR contacts : http://www.otcmarkets.com/financialReportViewer?symbol=POTN&id=183955
thanks for the summary- i concur. to me the good news is in the earnings. As in, they are actually making money and growing revenue. In ref to borrowing it is a necessary evil. Either you do a converting note, a share offering, or sell equity stake in the company. Or maybe you just have Jeff Bezos sending you free angel investor money. (kidding) lol. Either way, obtaining money for early stage growth is imperative and it is normally not feasible to use gross income to fund everything, even with the acquisition of another profitable company.
The key here is making sure management is not abusing the privilege of raising money at the expense of shareholder value and corp health. e.g. some companies in this sector are not making any revenue but keep "printing money" through convertibles and/or S/O. sort of a scam.
POTN appears to me they are intent on growing into a mature business, they have 100% executed on previously stated plans, and are positioned make a lot of money.
I also like FRLF and am presently studying it.
Disclaimer - I am long POTN a total of 200k shares as of this week
got in a quick buy at .06 at the bell. earnings look good so lets see what tomorrow brings.
"wall street" has no weigh in- they are too busy with FAANG / chip stocks and pumping other names du jour. but please do keep buying those names you've made my short sales very profitable in November (roku, overstock, amd etc).
Unfortunately, lemmings don't usually get to be rich.